fluorescein ophthalmic (OTC)

  • Print
Brand and Other Names:BioGlo, Fluorets, more...Ful-Glo

Dosing & Uses

AdultPediatric

Dosing Form & Strengths

ophthalmic strips

  • 0.6mg
  • 1mg

solution, injection

  • 10%
  • 25%

Eye Examination

Diagnostic staining

  • Ophthalmic strips are indicated for staining the anterior segment of the eye during eye examinations
  • Moisten by applying 1-2 gtt sterile isotonic irrigation solution, sterile water, or other ophthalmic solution  
  • Application: While patient looks down, stroke applicator tip across bulbar conjunctiva for fornix; then have patient blink several time
  • Alternative application methods include having patient close lid tightly over strip until desired amount of staining occurs for exam

Ophthalmic angiography

  • If allergy reaction a possibility, use an intradermal test dose of 0.05 mL; evaluate 30-60 min following intradermal injection; a negative test dose does not exclude potential for allergic reaction; immediate treatment for anaphylaxis, including epinephrine 1:1000 should be available during the procedure
  • Intravenous
    • May administer using a 23 gauge needle attached to small syringe; take steps to ensure needle has not extravasated prior to turning off room light  
    • Administer 500 mg as single dose IV into antecubital vein; in cases where a highly sensitive imaging system used (eg, scanning laser ophthalmoscope), may administer a dose of 200 mg; inject dose into antecubital vein over 5-10 sec; luminescence appears 7-30 sec following injection; maintain venous access following procedure in event treatment is needed for anaphylaxis
  • Oral (off-label)
    • Administer 1 g of injection solution orally; clarity of photographs reportedly poorer than photographs obtained following IV administration

Dosing Form & Strengths

ophthalmic strips

  • 0.6mg
  • 1mg

solution, injection

  • 10%
  • 25%

Eye Examination

Diagnostic staining

  • Ophthalmic strips are indicated for staining the anterior segment of the eye during eye examinations
  • Moisten by applying 1-2 gtt sterile isotonic irrigation solution, sterile water, or other ophthalmic solution  
  • Application: While patient looks down, stroke applicator tip across bulbar conjunctiva for fornix; then have patient blink several time
  • Alternative application methods include having patient close lid tightly over strip until desired amount of staining occurs for exam

Ophthalmic angiography

  • If allergy reaction a possibility, use an intradermal test dose of 0.05 mL; evaluate 30-60 min following intradermal injection; a negative test dose does not exclude potential for allergic reaction; immediate treatment for anaphylaxis, including epinephrine 1:1000 should be available during the procedure
  • May administer using a 23 gauge needle attached to small syringe; take steps to ensure needle has not extravasated prior to turning off room light  
  • Administer 3.5 mg/lb (7.7 mg/kg) as single dose IV into antecubital vein over 5-10 sec; not to exceed 500 mg; luminescence appears 7-30 sec following injection; maintain venous access following procedure in event treatment is needed for anaphylaxis
Next:

Adverse Effects

Frequency Not Defined

Seizure

Dizziness

Headache

Cardiac arrest (rare)

Shock

Hypotension

Syncope

Basilar artery ischemia (rare)

Pruritus GI distress

Skin discoloration (yellow)

Hives

Taste disturbance

Vomiting

Urine discoloration

Dermatitis

Extravasation

Thrombophlebitis

Bronchospasm

Postmarketing reports

Pulmonary edema (acute)

Respiratory arrest

Sickle cell crisis

Localized nerve palsy

Hemolytic anemia

Previous
Next:

Warnings

Contraindications

Hypersensitivity to components or mercury-containing compounds; history of hypersensitivity to fluorescein sodium

Cautions

Severe local tissue damage, including phlebitis, skin sloughing, toxic neuritis, may occur from extravasation; use caution; discontinue immediately if extravasation occurs

Use caution in patients with history of hypersensitivity, allergies, or asthma

Skin may turn yellow within few minutes of administration and fade in 6-12 hr; urine may appear bright yellow for 24-36 hr

Not for intrathecal or arterial administration

Nausea and/or vomiting and gastrointestinal distress may occur commonly within few minutes following injection; may subside within 10 min

Remove contact lenses before use to avoid staining; after exam, flush eye with saline eye drops and wait at least 1 hr before reinserting contact lenses

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Excreted into breast milk; American Academy of Pediatrics classifies fluorescein as compatible with breast-feeding

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Indicator dye and diagnostic aid; emits fluorescence when exposed to blue wavelength

Distribution

Vd: 0.5 L/kg

Elimination

Excretion: Urine

Metabolism

Rabidly metabolized to fluorescein monoglucuronide (80%) within 1 hr following IV administration

Previous
Next:

Images

Previous
Next: